Close Menu

Benitec

Roughly eight years after it shuttered its US operations due to financial pressures, Australia's Benitec Biopharma is preparing to set up a modest laboratory in Northern California.

Amid a resurgence of investor interest in RNAi as a therapeutic modality, two of the field's smaller players this week announced financing arrangements expected to help them reach key inflection points — news that prompted double-digit jumps in each company's share price.

Should Dicerna Pharmaceuticals complete its planned initial public offering, the company would be the first RNAi drug developer to go public since Alnylam Pharmaceuticals did so in 2004.

Benitec Biopharma announced this week that it has submitted an investigational new drug application to begin phase I/IIa testing of its expressed RNAi-based hepatitis C treatment TT-034.

With an investigational new drug application ready for submission to US regulators, Australian firm Benitec Biopharma anticipates launching a phase I/IIa study of its hepatitis C treatment TT-034 before the end of the year, the company's chief executive said this week.

Arrowhead Research has named David Lewis as its new chief scientific officer.

Australian expressed RNAi firm Benitec Biopharma provided an update on its research and development activities late last month, reporting that it remains on track to move its lead drug candidate, the hepatitis C therapy TT-034, into the clinic as early as this month.

Benitec Biopharma has named CEO Peter French as a managing director.
French joined Benitec in 2009 as CSO and was promoted to CEO in 2010.

NEW YORK (GenomeWeb News) – Benitec Biopharma today announced a licensing agreement with the University of New South Wales for use of the university's RNAi technology and to develop a companion diagnostic to identify patients who may develop resistance to chemotherapy.

Benitec Biopharma this week announced that it has licensed its proprietary expressed RNAi technology to Regen BioPharma, a San Diego-based subsidiary of Bio-Matrix, for use in developing cancer vaccines.

Pages

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.